Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Squamous Cell Carcinoma of Head and Neck 2Tongue Neoplasms 1Salivary Gland Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Melanoma 1Lymphoma 1Head and Neck Neoplasms 1Fallopian Tube Neoplasms 1Colorectal Neoplasms 1Carcinoma, Squamous Cell 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Brenner Tumor 1Breast Neoplasms 1

Interventions

Carboplatin 40Paclitaxel 30Bevacizumab 16Gemcitabine 14Cyclophosphamide 14liposomal doxorubicin 13Taxes 12Topotecan 11Cisplatin 11Docetaxel 7veliparib 6pembrolizumab 6olaparib 6Doxorubicin 6Magnetic Resonance Spectroscopy 5Albumin-Bound Paclitaxel 5sargramostim 4fludarabine 4aldesleukin 4Specimen Handling 4Oxaliplatin 4Leucovorin 4Immunoglobulin G 4Filgrastim 4Drug Therapy 4Disulfides 4Biopsy 4talazoparib 3mirvetuximab soravtansine 3Radiotherapy 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Fallopian Tube Neoplasms × VTX-2337 × Clear all
NCT01294293 2014-12-25

TLR8 Agonist VTX-2337 and Pegylated Liposomal Doxorubicin Hydrochloride or Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer

GOG Foundation

Phase 1 Completed
20 enrolled
Gynecologic

Brenner Tumor, Fallopian Tube Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡